112 related articles for article (PubMed ID: 17893873)
1. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R
Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
Sánchez-Arévalo Lobo VJ; Aceves Luquero CI; Alvarez-Vallina L; Tipping AJ; Viniegra JG; Hernández Losa J; Parada Cobo C; Galán Moya EM; Gayoso Cruz J; Melo JV; Ramón y Cajal S; Sánchez-Prieto R
Biochem J; 2005 Apr; 387(Pt 1):231-8. PubMed ID: 15540985
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
4. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
5. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.
Galan-Moya EM; de la Cruz-Morcillo MA; Llanos Valero M; Callejas-Valera JL; Melgar-Rojas P; Hernadez Losa J; Salcedo M; Fernández-Aramburo A; Ramon y Cajal S; Sánchez-Prieto R
PLoS One; 2011; 6(12):e28406. PubMed ID: 22164285
[TBL] [Abstract][Full Text] [Related]
6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
7. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
8. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM
Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
Youlyouz-Marfak I; Gachard N; Le Clorennec C; Najjar I; Baran-Marszak F; Reminieras L; May E; Bornkamm GW; Fagard R; Feuillard J
Cell Death Differ; 2008 Feb; 15(2):376-85. PubMed ID: 17992189
[TBL] [Abstract][Full Text] [Related]
10. [Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway].
Hu RH; Jin WN; Chang GQ; Lin YN; Wang J; Ru YX; Li QH; Pang TX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1341-5. PubMed ID: 23257429
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
13. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
14. A novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS‑mediated c‑Abl/p38 MAPK signaling.
Chung KS; Han G; Kim BK; Kim HM; Yang JS; Ahn J; Lee K; Song KB; Won M
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1315-24. PubMed ID: 24121479
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R
Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
19. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
